Regulatory Scrutiny Intensifies for Hims & Hers Amid Growth Pivot

Hims & Hers stock gains despite FDA warning on GLP-1 ads. Company halts some compounded sales, projects $65M revenue hit, and pivots to core health segments and international expansion.

Shares of the telehealth platform Hims & Hers advanced nearly 4% on Wednesday, a move that came despite the company receiving a formal warning letter from the U.S. Food and Drug Administration. The regulator cited misleading advertising for compounded versions of GLP-1 weight-loss medications, placing Hims & Hers among 30 providers targeted in this enforcement action.

Strategic Shift Follows Legal and Regulatory Challenges

The regulatory landscape for telehealth companies offering weight-management solutions is tightening. The FDA has declared an end to supply shortages for key active ingredients like semaglutide and tirzepatide, effectively closing a previous avenue for compounded alternatives—custom-mixed versions of patented drugs. This pressure escalated in February when pharmaceutical giant Novo Nordisk filed a patent infringement lawsuit against Hims & Hers, specifically targeting its personalized formulations.

In response, the company's management halted sales of certain compounded products. This decision carries a direct financial impact: Hims & Hers anticipates a $65 million revenue shortfall in the first quarter of 2026, attributed solely to new shipping restrictions for these personalized weight-loss preparations.

Confidence in Core Business and Expansion Plans

Leadership has moved to project assurance, focusing investor attention on segments beyond the contested weight-loss category. During the recent Morgan Stanley Technology, Media, and Telecom Conference, the finance team highlighted the robust performance of its dermatology, mental health, and hormone therapy divisions. These areas are presented as profitable, stable-growth pillars of the business.

This messaging appears to resonate with the market. It followed a prior short squeeze event that propelled the stock 13% higher as heavily shorted positions were unwound.

The company's underlying growth metrics remain strong. For the full 2025 fiscal year, Hims & Hers reported revenue of $2.35 billion, representing a 59% year-over-year increase. Its subscriber base now exceeds 2.5 million users. The cash flow generated is funding a significant strategic repositioning, including a planned acquisition of the international health platform Eucalyptus for up to $1.15 billion. This deal is designed to provide access to key markets in Australia and Japan.

The broader strategic aim is to reduce reliance on the U.S. market for GLP-1-related products through both geographic diversification and portfolio expansion. Whether this pivot can sufficiently offset near-term regulatory setbacks will depend on the speed and success of its international growth initiatives.